Here, we conduct a systematic evaluation of dapagliflozin’s effects on cardiac function indicators, including NT-proBNP, LVEF, LVEDD, and LVESD (26), and the incidence of adverse cardiovascular outcomes such as angina pectoris, heart failure, and rehospitalization due to heart failure. This evidence concerns the gene NPPB and angina pectoris.